title: Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation.
authors.affiliation: Centro de Oncologia e Hematologia Familia Dayan Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: G F
authors.initials: GF
authors.lastname: Perini
authors.affiliation: Centro de Oncologia e Hematologia Familia Dayan Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil.|Foundation Medicine Inc, Cambridge, MA, USA.
authors.forename: P V
authors.initials: PV
authors.lastname: Campregher
authors.affiliation: Foundation Medicine Inc, Cambridge, MA, USA.|Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Foundation Medicine Inc, Cambridge, MA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ali
authors.affiliation: Centro de Oncologia e Hematologia Familia Dayan Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: N
authors.initials: N
authors.lastname: Hamerschlak
authors.affiliation: Centro de Oncologia e Hematologia Familia Dayan Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: F P S
authors.initials: FP
authors.lastname: Santos
mesh_terms: D000328:Adult; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D009154:Mutation; D016896:Treatment Outcome; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: C000624653:TSC2 protein, human; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; D000068338:Everolimus